10 min read · updated 2026-10-31
Peptide FDA Status 2026, Compound by Compound: BPC-157, TB-500 and More
Where each research peptide stands under the 503A framework in October 2026, and what the April removals and July votes did and did not change.
The framework these actions operate within
Section 503A of the Federal Food, Drug, and Cosmetic Act governs which bulk drug substances state-licensed compounding pharmacies may use when preparing a preparation against an individual prescription. While the FDA evaluates a nominated substance it sits in one of three interim categories. Category 1 covers substances under evaluation where the agency does not intend enforcement action during review. Category 2 covers substances the agency has identified as raising significant safety concerns, which in practice blocks compounding. Category 3 covers substances nominated without adequate supporting information. None of this framework governs research supply, and none of it constitutes drug approval — a separate process requiring demonstration of safety and effectiveness for a specific indication.
What happened in April 2026
On 15 April 2026 the FDA published notice removing twelve peptide substances from Category 2 of the 503A bulk drug substances list, effective 22 April. The twelve were BPC-157, LL-37, DiHexa acetate, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, PEG-MGF, melanotan II, MOTS-c, semax, and TB-500. The mechanism matters and was widely misreported: the substances came off Category 2 because the parties who had nominated them withdrew those nominations, not because the agency made a finding that they were safe to compound. Removal from Category 2 lifts a prohibition designation. It does not place a substance on the affirmative 503A list, which requires a separate process.
What the July 2026 advisory vote did
The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider whether seven of the removed peptides should be added to the affirmative 503A list. It recommended six — BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon — and recommended against emideltide. The votes were close and, unusually, went against the written recommendation of FDA scientific staff, who had opposed adding any of the seven. The committee considered both free base and acetate forms. A second meeting covering additional substances is expected in February 2027, with injectable GHK-Cu on a separate track.
What none of it changed
An advisory committee recommendation is not a decision. The FDA is not bound by it, and formal addition to the 503A list requires notice-and-comment rulemaking — a proposed rule, a comment period, review, and a final rule. As of mid-October 2026 no such rule has been finalised for any of these substances, none has been added to the affirmative list, and none is an FDA-approved drug. The practical position is unchanged from before April: these are unapproved substances, not authorised for compounding under a settled framework, and not approved for human use in any form. The one development since is the HHS enforcement discretion policy of 30 October 2026 for six of them, described below; it is discretion, not authorisation.
Status by compound, October 2026
The sections below place each commonly discussed research peptide in its current position under the 503A framework, as of mid-October 2026, updated on 31 October 2026 for the HHS enforcement discretion policy published on 30 October. Compounds that are the active ingredient of an approved drug are not covered here, because their compounding status is governed by the approved drug rather than by the interim categories. For every compound listed, the answer to whether it is an approved drug is the same: it is not.
The 30 October 2026 enforcement discretion policy
On 30 October 2026 the Federal Register published an HHS notice titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (document 2026-22192), signed by the Secretary of Health and Human Services. It says the agency does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician compounding BPC-157, TB-500, KPV, MOTS-c, semax or epitalon under section 503A, provided every condition in the policy is met. The conditions include sourcing the bulk substance from an FDA-registered facility with a valid certificate of analysis, a registered manufacturer following current good manufacturing practice, one active ingredient per preparation, specified labeling, and reporting of serious adverse events. The policy does not add any of the six to the 503A bulks list and is not an approval of any drug. It applies only to compounding under section 503A and does not change the status of research-use-only material; HHS describes one of its aims as discouraging the widespread use of research-use-only peptides supplied by foreign manufacturers. Written comments were accepted for two weeks after publication, and HHS says it may revisit the policy if a safety signal or product-quality issue emerges.
Recommended in July 2026, enforcement discretion from 30 October
BPC-157, TB-500, KPV, MOTS-c, semax and epitalon were removed from Category 2 effective 22 April 2026 after their nominations were withdrawn, and the advisory committee recommended all six for the 503A bulks list on 23 and 24 July 2026, in each case by a narrow margin and against the written recommendation of agency staff. Since 30 October 2026 they are covered by the HHS enforcement discretion policy described above. As of 31 October 2026 no proposed or final rule adding any of them to the bulks list has been published. Enforcement discretion is not a listing and not an approval, and it can be withdrawn.
Removed from Category 2 but not recommended
Emideltide, also referred to as DSIP, came off Category 2 with the same April group, but the committee voted against recommending it for the bulks list in July. It remains an unapproved substance with no pathway to compounding under consideration.
Removed from Category 2, awaiting committee review
LL-37, dihexa acetate, melanotan II, PEG-MGF and the injectable forms of GHK-Cu were also removed from Category 2 in April 2026. The agency has said the advisory committee will consider them at a meeting before the end of February 2027; no date has been set. Non-injectable GHK-Cu is handled separately and is listed in Category 1.
Withdrawn in 2024 and voted down
AOD-9604, CJC-1295, ipamorelin and thymosin alpha-1 left Category 2 earlier, in September 2024, when their nominations were withdrawn. The advisory committee then voted against adding each of them to the bulks list at its meetings of 29 October and 4 December 2024. None is an approved drug, and none is on a path to the bulks list.
Still in Category 2
Kisspeptin-10 remains in Category 2 of the 503A interim list, the category for substances the agency has identified as raising significant safety concerns, and the advisory committee voted against it in October 2024. Ibutamoren, a non-peptide secretagogue often discussed alongside these compounds, is also in Category 2.
Category 1, Category 3, and not listed
Several compounds sit in other parts of the framework. NAD, glutathione, methylcobalamin and vasoactive intestinal peptide are listed in Category 1, meaning the agency does not intend to take enforcement action against compounding while it evaluates them. Thymulin and ARA-290 are in Category 3, for substances nominated without adequate supporting information. Selank was formerly in Category 2 and its nomination has since been withdrawn. Others, including 5-amino-1MQ, humanin and IGF-1 LR3, do not appear on the interim lists at all. Category 1 is a statement about enforcement during review, not an approval.
Why the coverage has been wrong
Three distinct things are routinely collapsed into one. Removal from a prohibition list, recommendation for an authorisation list, and drug approval are separate events with separate legal consequences, and only the first two have occurred. Headlines describing the April action as the FDA clearing or approving these compounds described something that did not happen; the same pattern repeated after July. The underlying reason the error persists is that each step sounds like progress toward availability, and the distance between an advisory recommendation and a final rule is not obvious to a general reader. Anyone relying on these reports to conclude that regulatory status has materially changed has been misled.
What this means for research supply
Nothing in either action alters the research use only designation or the obligations attached to it, and the same is true of the HHS enforcement discretion policy of 30 October 2026, which concerns compounding only. The 503A framework governs pharmacy compounding for individual patients under prescription — a different activity, under a different statutory provision, from the supply of material for laboratory investigation. Compounds discussed in this guide remain unapproved for human use regardless of where they sit in the compounding review. A supplier describing these actions as a change in the status of research material is describing something that did not occur.
Sources
The answers under Frequently asked were checked against these sources on 20 October 2026.
- OIRA pending review listing: Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94
- Federal Register, 30 October 2026: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances
- STAT / AP, 15 October 2026
- Holland & Knight: Peptides at a crossroads, October 2026
Frequently asked
Did the FDA approve BPC-157 in 2026?
No. The April 2026 action removed it from Category 2 of the 503A compounding list, and the July advisory committee recommended it for the affirmative list. Neither is drug approval, which is a separate process. BPC-157 remains an unapproved substance.
Can compounding pharmacies prepare these peptides now?
Not under a settled framework. The advisory committee recommendation is not binding, and formal addition to the 503A list requires notice-and-comment rulemaking that has not concluded as of 31 October 2026. Since 30 October 2026, however, an HHS enforcement discretion policy says the agency will not take enforcement action against licensed 503A compounding of BPC-157, TB-500, KPV, MOTS-c, semax and epitalon when set conditions are met. That discretion is not a listing and can be withdrawn.
Why were the peptides removed from Category 2?
Because the parties who nominated them withdrew those nominations, which is a procedural event. The removal was not a finding by the agency that the substances are safe to compound.
Are these compounds banned in competitive sport?
Many are. The World Anti-Doping Agency maintains a prohibited list that includes several growth factor and secretagogue classes, and it is updated annually. Athletes subject to testing should check the current list directly rather than rely on a supplier summary.
What is the FDA status of TB-500 in 2026?
TB-500 is not an approved drug. It was removed from Category 2 of the 503A compounding list effective 22 April 2026 and recommended for the 503A bulks list by the advisory committee in July 2026. On 30 October 2026 HHS published an interim policy saying it will not take enforcement action against licensed 503A compounding of TB-500 under set conditions, but as of 31 October 2026 no rule adding it to the bulks list has been published.
Which peptides are still in FDA Category 2 in 2026?
Of the research peptides commonly discussed, kisspeptin-10 remains in Category 2 as of October 2026. The twelve substances removed in April 2026, including BPC-157, TB-500 and melanotan II, are no longer in Category 2, though none of them is an approved drug.
When will the FDA decide on BPC-157?
There is no scheduled date for a final decision. Adding BPC-157 to the 503A bulks list would require a proposed rule, a public comment period and a final rule, and as of 31 October 2026 no proposed rule has been published. In the meantime, an HHS enforcement discretion policy published on 30 October 2026 covers licensed 503A compounding of BPC-157 under set conditions. It is not a listing or an approval and can be withdrawn.
Are any of these research peptides approved drugs?
No. Several peptide drugs are approved for specific indications under their own applications, but none of the research compounds covered in this guide is an approved drug, and none of the 2026 actions changed that.
What is the HHS enforcement discretion policy for compounded peptides?
It is a notice published in the Federal Register on 30 October 2026 (document 2026-22192), titled Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. It was sent to the White House Office of Management and Budget on 14 October 2026 under the working title Interim Access Policy for Compounding Using Certain Peptides. HHS says it will not take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding BPC-157, TB-500, KPV, MOTS-c, semax or epitalon under section 503A when every listed condition is met. It does not approve any peptide as a drug and does not add any peptide to the 503A bulks list, which still requires notice-and-comment rulemaking. It covers compounding only, not research-use-only material, and HHS may revisit it if a safety signal or product-quality issue emerges.
See the practice, not just the principle
Every lot we release is published in full — assay, method, and measured result — and the record stays online after the lot sells out.
Open the COA library